Home » Business News » 2012 » July » July 17, 2012

Equity Briefing Healthcare Review: Alnylam Pharmaceuticals & Human Genome Jump On Positive News

July 17, 2012 - Vancouver

Human Genome Sciences (NASDAQ:HGSI) shares climbed 4.60% to $14.20 after GlaxoSmithKline and Human Genome Sciences today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share incash. The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of US$7.17 per share on 18 April 2012.The Boards of Directors of both companies have approved the transaction.

Zogenix, Inc. (NASDAQ:ZGNX) shares increased 4.52% to $2.31 after the company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)for Zohydro ER (hydrocodone bitartrate extended-release capsules), Zogenix's lead investigational product candidate for the treatment of moderate to severe chronic pain.

St. Jude Medical, Inc. (NYSE:STJ) stock fell 0.41% to $38.75 after the company announced initial findings from the Riata(R) Lead Evaluation Study. The study's phase-one results found that externalized conductors occurred in 9.3% of the smaller-diameter Riata ST 7F leads in the study, and in 24% of the larger-diameter Riata 8Fleads.

Nanosphere, Inc. (NASDAQ:NSPH) stock declined 1.34% to $2.95 after the company announced preliminary results for the second quarter ended June 30, 2012. The company reported second quarter 2012 revenues of $1.3 million as compared to $0.5million for the same period in 2011 owing to new customer placements. Customer placements for the second quarter 2012 were 25 bringing the cumulative placements to 166.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock surged 33.55% to $16.72 after the company announced the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). Results from this study showthat administration of ALN-TTR02 leads to robust knockdown of serum TTR protein levels of up to 94%; the overall results were highly significant.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Equity Briefing via Thomson Reuters ONE

Copyright (c) Thomson Reuters 2012. All rights reserved.

Copyright 2012 ACN Newswire. All rights reserved.

ACN Newswire

Comment on this story